Identification of a novel metabolism-related prognostic signature in hepatocellular carcinoma through bioinformatics analysis and validation through experimental studies

Zhihao Wang¹, Kidane Siele Embaye¹, Qing Yang², Lingzhi Qin¹, Chao Zhang¹, Liwei Liu¹, Xiaoqian Zhan¹, Fengdi Zhang³, Xi Wang¹, Shenghui Qin¹

¹ Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;

² Department of Pharmacy, Hiser Medical Center of Qingdao, Qingdao 266033, China;

³ Department of Pathology, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan 430030, China;

Correspondence to: Shenghui Qin;

Email: 2015tj0147@hust.edu.cn;
Abstract

Background: Given that metabolic reprogramming has been recognized as an essential hallmark of cancer cells, this study sought to investigate the potential prognostic values of metabolism-related genes (MRGs) for hepatocellular carcinoma (HCC) diagnosis and treatment.

Methods: The metabolism-related genes sequencing data of HCC samples with clinical information were obtained from the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). The differentially expressed MRGs were identified by Wilcoxon rank sum test. Then, univariate Cox regression analysis was performed to identify metabolism-related DEGs that related to overall survival (OS). A novel metabolism-related prognostic signature was developed using the least absolute shrinkage and selection operator (Lasso) and multivariate Cox regression analyses. Furthermore, the signature was validated in the TCGA dataset. Finally, the expression levels of hub genes were validated in cell lines by Western blotting (WB) and quantitative real-time PCR (qRT-PCR).

Results: A total of 178 differentially expressed MRGs were detected between the ICGA dataset and the TCGA dataset. We found that 17 MRGs were most significantly associated with OS by using the univariate Cox proportional hazards regression analysis in HCC. Then, the Lasso and multivariate Cox regression analyses were applied to construct the novel metabolism-relevant prognostic signature, which consisted of six MRGs. The prognostic value of this prognostic model was further successfully validated in the TCGA dataset. Further analysis indicated that this
signature could be an independent prognostic indicator after adjusting to other clinical factors. Six MRGs (FLVCR1, MOGAT2, SLC5A11, RRM2, COX7B2, and SCN4A) showed high prognostic performance in predicting HCC outcomes. Finally, hub genes were chosen for validation and the expression of FLVCR1, SLC5A11, and RRM2 were significantly increased in human hepatocellular carcinoma cell lines when compared to normal human hepatic cell line, which were in agreement with the results of differential expression analysis.

**Conclusions:** In summary, our data provided evidence that the metabolism-based signature could serve as a reliable prognostic and predictive tool for overall survival in patients with HCC.

**Keywords:** Hepatocellular carcinoma, Metabolism-related genes, Prognostic signature, Survival

**Background**

According to the 2018 Global Cancer Statistics, liver cancer is the sixth most common human malignancies worldwide (841,080 cases/year) and the fourth leading cause of cancer-related deaths (781,631 cases/year) [1]. Hepatocellular carcinoma (HCC) originates from hepatocytes and accounts for the vast majority (approximately 75%-85%) of primary liver cancer. Despite recent advances in early detection and management, the mortality is still high due to its late detection and the low rate of early diagnosis [2]. Therefore, it is urgently necessary to identify effective prognostic
biomarkers and therapeutic targets to complement and improve current screening strategies for HCC diagnosis and prognosis.

Recently, metabolic reprogramming has been recognized as a novel and essential hallmark of cancer cells[3]. Cancer cells regulate their metabolism to promote the production of energy, the synthesis of macromolecules and the maintenance of redox balance, so as to support their rapid cell growth and proliferation[4, 5]. Increased glycolysis under normoxic condition (Warburg effect) and glutamine metabolism are the best characterized metabolic change in tumor cells[5, 6]. Accumulating studies have indicated that abnormal metabolism are associated with a poor prognosis of many tumor types, including HCC[7, 8]. Luo et. al [9]screened the combination of phenylalanyl-tryptophan and glycine as liver cancer metabolic markers, and confirmed that their diagnostic sensitivity was superior to AFP. A series of combined markers, such as lactic acid, glycolamine, phenylalanine, aconitric acid and ribose, were screened for identification of patients with and without recurrence[10]. A recent study revealed thousands of metabolism-relevant genes encoding all known human metabolic enzymes and transporters [11], however, the definitive role and underlying mechanisms of them in the development and prognosis of HCC remains poorly understood. More importantly, there are few models based on metabolism-related genes to predict the prognosis of HCC patients. Thus, it is of great clinical significance to establish a novel metabolism-related prognostic signature that can reliably predict the prognosis of HCC.

In this study, we identified the differentially expressed MRGs in HCC patients by associating the gene expression profiles with MRGs in TCGA database and the ICGC
database. The functional enrichment analysis and prognostic value of the differentially expressed MRGs were also determined. The prognostic model was finally established based on Cox regression and Lasso regression analyses. To verify the accuracy of the model, the Kaplan-Meier (KM) estimator and the receiver operating characteristic (ROC) curve were applied. Moreover, the prognostic value of our metabolism-related prognostic model was further validated in TCGA database.

Materials and methods

Data collection

The transcriptomic and the corresponding clinical data of patients with hepatocellular carcinoma (HCC) were downloaded from the the International Cancer Genome Consortium (ICGC; https://icgc.org/) and The Cancer Genome Atlas (TCGA; https://portal.gdc.cancer.gov/) databases. The RNA-seq data, including 243 HCC and 202 adjacent non-tumor cases from ICGC database and 374 HCC and 50 adjacent non-tumor cases from TCGA database were examined. The current study did not require ethics approval because all data had been collected from public availability of data in the ICGC database and TCGA database.

The differentially expressed MRGs screening

2752 metabolism-related genes (MRGs), which have been reported to encode all known human metabolic enzymes and transporters, were obtained from the Possemato’s research[11]. The differentially expressed MRGs in HCC and normal tissues were
detected using the Wilcoxon test method[12]. |logFC|>1 and adjusted P<0.05 were considered as significant. The common differentially expressed MRGs were identified between the ICGC database and the TCGA database by used FunRich software. These intersection MRGs were selected for further analysis.

**Functional enrichment analysis of MRGs**

Gene Ontology (GO) [13]and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis[14] were performed by “clusterprofiler” R package and “enrichplot” R package in R software[15]. Functional categories with false discovery rate(FDR) of less than 0.05 were considered statistically significant.

**Survival-associated MRGs**

We collected clinical information of 232 HCC patients in the ICGC database. A total of 3 patients who were followed for less than 2000 days and more than 30 days were excluded to avoid the interference of irrelevant factors. Survival analysis was performed on 229 patients. To screen out MRGs associated with the prognosis in HCC patients, univariate Cox analysis was implemented by the R “survival” package, and data were visualized using forest plots. Only differentially expressed MRGs a P value < 0.001 were were screened for subsequent analyses.

**Construction of metabolism-related signature for HCC**

HCC patients in ICGC dataset were used for constructing the COX prognostic signature,
and patients in TCGA dataset were used for validating the signature. Lasso and multivariate Cox regression analyses were performed to construct a prognostic model[16]. To avoid the prognostic signature overfitting and remove highly related survival-related MRGs, Lasso Cox regression was carried out using R “survival” and “glmnet” package. MRGs detected via Lasso algorithm were evaluated by step wise multivariate Cox regression analysis. By weighting the estimated Cox regression coefficients, the model of tumor-related metabolism genes risk was constructed[17]. The prognostic metabolism-related gene signatures were shown as risk score = Σ (βi × Expi), where βi, the coefficients, represented the weight of the respective signature and Expi represented the expression value. Based on the risk score formula, patients were assigned into low-risk group and high-risk group with the median risk score as the cutoff point. The Kaplan-Meier (K-M) survival curve was used the log-rank test to evaluate the differences in survival rate between the two groups. Furthermore, the receiver operating characteristic (ROC) curve was implemented by R “survivalROC” package[18] and the corresponding area under the ROC curve (AUC) was measured to assess the sensitivity and specificity of the metabolism-related signature.

**Validation of metabolism-related signature**

To verify the prognostic value of metabolism-related signature, we used the TCGA database as the validation cohort. The same formula was used to calculate the risk scores for each patient. Survival and ROC curve analyses were implemented as described above. In addition, Univariate and multivariate analyses were used to
estimate the effect of risk scores on overall survival and the clinicopathologic features. We also explored the correlation between the expression of these MRGs and several clinical features. For further validation of our analysis, The Human Protein Atlas (HPA) online database (http://www.proteinatlas.org/) was applied to identify the expression of these MRGs at a translational level [19].

**Cell culture**

Human normal hepatocyte cell line (LO2) and HCC cell lines (HepG2, Hep3B, HLF and PLC/PRF/5) obtained from the laboratory were maintained in the DMEM medium (Gibco, Wuhan, China) with 10% heat-inactivated fetal bovine serum (FBS, GibcoBRL) and antibiotics of 1% streptomycin and penicillin at 37°C in an atmosphere of 5% CO2.

**Quantitative real-time PCR**

Total RNA from collected cells was extracted using TRIzol reagent. Quantitative real-time PCR was performed as described previously[20]. The used primer pairs were as follows: human SLC5A11 (forward 5'-CCAAGGACATTCCAGCCTGG-3' and reverse 5'-GAAGCCATAGAAAACAGCGGG-3'), human FLVCR1 (forward 5'-AGCTCTTCAAGACATGCCCCTCC-3' and reverse 5'-TTAGCCCCATCCTCCAGCA-3'), human RRM2 (forward 5'-CCAAGGACATTCCAGCCTGG-3' and reverse 5'-GAAGCCATAGAAAACAGCGGG-3'), and human GAPDH (forward 5'-TCAAGAAGGTTGGTAAGCAGG-3' and reverse 5'-
The results were normalized to GAPDH.

**Western Blotting Analysis**

The protein extraction, and western blot analysis were performed as described previously[21].

**Statistical analysis**

All statistical analyses were performed by version 3.6.1 of R software(https://www.r-project.org/) and version 3.1.3 of FunRich software(http://www.funrich.org/), along with version 3.7.2 of Cytoscape software (http://www.cytoscape.org/). If not otherwise stated, data were considered to be statistically significant with P value <0.05.

**Results**

**Identification of differentially expressed MRGs**

A total of 2752 MRGs that encoded all known human metabolic enzymes and transporters were obtained from the Possemato’s study[11], and we matched these genes with the sequence data of HCC related mRNA in the ICGC and TCGA databases; the differentially expressed MRGs between HCC and normal samples were identified by Wilcoxon rank sum test. Considering the cutoff criteria (adjusted P value <0.05 and |log FC| > 1.0), 475 differentially expressed MRGs (consisting of 94 downregulated and 381 upregulated genes) were extracted from in the ICGC database(Fig.1a, 1c), 251 differentially expressed MRGs (consisting of 36 downregulated and 215 upregulated
genes) were extracted from the TCGA database (Fig. 1b, 1d). Finally, the common differentially expressed MRGs were identified in the two databases, a total of 178 MRGs (consisting of 28 downregulated and 150 upregulated genes) (Fig. 1e) were selected for subsequent analysis.

**GO, KEGG and PPI analysis of metabolism-related DEGs**

To evaluate the potential molecular mechanisms of MRGs in HCC, the 178 differentially expressed MRGs were further analyzed by GO functional annotation and KEGG pathway enrichment. The results showed the top 10 biological processes GO terms, cellular component GO terms, molecular function GO terms (Fig. 2a), and the top 10 KEGG pathway terms (Fig. 2c). The correlation between the intersection genes and the top 5 biological processes, including organic anion transport, organic acid transport, carboxylic acid transport, lipid catabolic process, and monovalent inorganic cation transport is shown in Figure 2b. The KEGG analysis showed that the intersection genes were associated with material metabolism, especially arachidonic acid metabolism.

**Prognostic values of survival-related MRGs**

To better define the characteristics of survival-related MRGs, we explored the differentially expressed MRGs associated with survival in HCC samples. In the univariate Cox proportional hazards regression analysis, 17 genes with significant effects on prognosis were identified. The resulting forest plot shown in Figure 3a
demonstrates that 15 genes have the characteristics of HR>1, whereas 2 genes have the characteristics of HR<1. This suggests that most survival-related MRGs were risk factors for HCC prognosis. Furthermore, scatter plots were visualized to display the expression patterns of 17 differentially expressed MRGs between HCC and normal tissues in ICGC database(Fig.3b) and TCGA database(Fig.3c). Scatter plot showing expression patterns of 1 down-regulated genes (MOGAT2) and 16 up-regulated genes (ASRGL1, COX7B2, MTHFD1L, B3GALNT1, ITPKA, SCN4A, PLCB1, NQO1, RRM2, FLVCR1, TMCO3, CAD, TK1, TYMS, SLC5A11 and SPNS1).

Construction of metabolism-related prognostic signature for HCC

To establish the metabolism-associated prognostic signature, the Lasso regression and multivariate Cox proportional hazards regression analyses were conducted. The Lasso regression analysis was applied to exclude genes that may be highly correlated with other genes (Fig.4a, 4b). Then, a prognostic signature model was established based on 6 MRGs selected from further multivariate Cox regression analysis(Fig.4c). Finally, a prognostic model was constructed to evaluate the prognosis of each patient as follows: Risk score = (0.031755×expression value of COX7B2) + (-2.27007×expression value of SCN4A) + (-0.15919 ×expression value of MOGAT2) + (0.164689×expression value of FLVCR1) + (0.02915×expression value of RRM2) + (0.068413×expression value of SLC5A11).

Then, the risk score of each patient was calculated according to this prognostic model. Based on the median risk score, 229 HCC patients were classified into a high risk group
(n = 114) and low risk group (n = 115). The risk score, survival status and gene expression heatmap of these prognostic MRGs are presented in Fig 5a-c. Kaplan-meier log-rank test indicated that patients in the high risk group showed markedly poorer overall survival than those in the low risk group (Fig. 5d). Areas under the curve value of the signature predicting the 1-, 3- and 4-year OS rates were 0.805, 0.803 and 0.94, indicating that this prognostic model exhibited a good sensitivity and specificity (Fig.5e). Since only one patient had a follow-up period of 5 years, we did not plot the ROC curve for 5 years.

**Validation of the metabolism-related prognostic signature by TCGA database**

The TCGA database including 193 HCC samples were used for the validation of the metabolism-related signature. According to the median risk score, we divided patients into high risk (n = 80) and low risk groups (n = 113). Consistent with the results derived from the ICGC dataset, the Kaplan-Meier curve demonstrated that patients in the high risk group exhibited markedly poorer overall survival than those in the low risk group (P < 0.001; Fig. 6d). The risk score, survival status and gene expression heatmap of these prognostic MRGs are shown in Fig 6a-c. The AUCs for 1-, 3- and 5-year OS rates were 0.721, 0.693 and 0.737 (Fig.6e). Univariate and multivariate Cox regression analysis was conducted to evaluate the independent prediction ability of metabolism-related prognostic signature between the signature and other common prognostic factors, including age, gender, histological grade, pathological stage and TNM stage. Although univariate Cox analysis indicated that pathologic stage, T stage and our model
were markedly associated with OS (Fig.6f, p<0.001), after the multivariate analysis, only metabolism-related prognostic signature(p<0.001) can be used as an independent prognostic factor (Fig. 6g). These results demonstrated that this prognostic model exhibited great applicability and stability in predicting the prognosis of HCC patients. To validate the MRGs in this model, the protein expression levels were analyzed using the HPA database. The results showed that FLVCR1, SLC5A11, MOGAT2, and RRM2 protein levels matched their mRNA expression levels (Fig.7). However, representative images of the SCN4A and COX7B2 protein levels were not available in the HPA database.

**Clinical value of prognostic signature**

To further evaluate the clinical value of MRGs, the relationship between MRGs prognostic indicators and clinical features were investigated, and the results indicated that FLVCR1, MOGAT2, RRM2, SCN4A, and COX7B2 were differentially expressed in patients with various clinical features (Fig.8). To validate the clinical value of the metabolism-related prognostic signature, the association between the risk score and clinical characteristics were subsequently assessed, and the results demonstrated that high risk scores were positively associated with histological grade, and survival status in patients with HCC (Fig.8).

**Validation of hub genes by WB and qRT-PCR**

In order to explore diagnostic biomarkers or therapeutic targets which may play more
significant roles in promoting HCC progression, we chose three genes (FLVCR1, SLC5A11 and RRM2) as our candidate biomarkers for WB and qRT-PCR validation in cell lines. As illustrated in Fig. 9, the expression levels of FLVCR1, SLC5A11 and RRM2 were significantly increased in human hepatocellular carcinoma cell lines compared with LO2, which were consistent with the results of bioinformatics analysis, indicating that the results were compelling.

**Discussion**

As a typical metabolic disease, the metabolic changes and regulatory mechanism of hepatocellular carcinoma are very complex, which has not been fully defined. HCC is different from normal liver tissue in glucose metabolism, lipid metabolism and protein metabolism, and also different from other tumors. These metabolic differences provide a theoretical basis for therapeutic strategies targeting tumor metabolism for HCC. Till date, there is no report on MRGs-based prognostic signatures for HCC patients. There is an urgent need to determine reliable metabolic biomarkers and predictive models to predict the prognosis of HCC.

In the current study, based on the analysis of ICGC dataset and TCGA dataset, 178 differentially expressed MRGs were screened. In order to better understand how differentially expressed MRGs are involved in biological processes and signal transduction processes, GO and KEGG enrichment analyses were conducted. The results of the GO enrichment revealed that the above genes were primarily related to metabolism response. The KEGG pathways were mainly focused on metabolism-
related pathways. In univariate regression analysis on the differentially expressed metabolism-related genes, 17 genes were detected to display significant association with OS. Then, the metabolism-related prognostic model based on six prognostic MRGs (FLVCR1, MOGAT2, RRM2, SCN4A, SLC5A11, and COX7B2) was constructed by the Lasso and multivariate Cox regression analyses. Using the model, every HCC patient was assigned a risk score. The differences in survival between patients with low and high scores were significant in both the ICGC cohorts and the TCGA cohorts. The ROC curves and AUCs indicated that models of the ICGC and TCGA cohorts both performed well. In addition, we further confirmed the important roles of MRGs in HCC through immunohistochemistry. Finally, FLVCR1, SLC5A11 and RRM2 were successfully validated with their high expression in HCC cell lines, which were in agreement with the results of bioinformatics analysis, indicating that bioinformatics analysis method were reliable.

Six metabolism related genes which constitute the prognosis model were identified as potential biomarkers of HCC. SLC5A11, an inositol-specific sodium-dependent glucose cotransporter responsible for inositol uptake, has been reportedly related to anaplastic thyroid carcinoma, but the relationship between SLC5A11 and HCC has not been described previously[22, 23]. In this study, our results indicated SLC5A11 may be as a potential oncogene in HCC. Ribonucleotide reductase M2 subunit (RRM2) plays an important role in the proliferation, invasion and metastasis of tumor cells, and thereby is involved in many types of malignancy including HCC[24-26]. A study by
Liu et al revealed that HBV induced the upregulation of RRM2 and promoted the development of HCC, while suppression of RRM2 inhibited the growth of HCC [27]. In accordance with these studies, the high expression of RRM2 may serve as a poor prognostic factor for HCC. Monoacylglycerol O-acyltransferase 2 (MOGAT2), a member of MOGAT gene family, plays an important role in the monoacylglycerol pathway for triacylglycerol synthesis and is highly expressed in the small intestine and liver of human[28, 29]. Previous studies have shown that MOGAT2 is an attractive target for the treatment of obesity, the treatment of obesity, type 2 diabetes mellitus(T2DM), and nonalcoholic steatohepatitis(NASH)[30, 31]. Wen et al. reported that MOGAT2 could have applications as a novel biomarker affecting the metastasis of colorectal cancer treatment[32]. However, little is known about the existence of molecular links between MOGAT2 and HCC. Sodium voltage-gated channel alpha subunit 4(SCN4A), encoding a skeletal muscle voltage-gated sodium channel, Nav1.4[33], has been reportedly associated with neuromuscular disorders like hypo- and hyperkalaemic periodic paralyses (hypoPP and hyperPP), paramyotonia congenita (PC), sodium channel myotonias (SCM) and congenital myasthenic syndrome[34]; however, its molecular mechanisms in cancers have not been explored. Liang et al. reported that the single nucleotide polymorphism (SNPs) of the cytochromo oxidase VIIb 2(COX7B2) gene was associated with familial nasopharyngeal carcinoma[35]. A study by Al et al revealed that COX7B2 is a susceptibility gene for type 2 diabetes in an extended Arab family[36]. In addition, little is known about the roles of COX7B2 in human cancers and other diseases. Feline leukemia virus subgroup C receptor
1(FLVCR1) encoding a ubiquitous heme exporter was demonstrated to promote the proliferation and tumorigenicity through inhibiting apoptosis and autophagy[37, 38]. Recently, Xian et al. reported that FLVCR1 showed the intracellular overproduction in HCC cell lines and that FLVCR1 expression was significantly associated with survival in HCC patients, which is consistent with our study[39].

Although our research provides new insights into the treatment of HCC, there are limitations to our study. First, the diagnostic efficiency and prognostic value of key genes were analyzed and verified only in TCGA dataset. Therefore, predictive performance need to be validated in other independent databases. Second, further experimental studies are needed to validate the predictive value of the six MRGs based on tumor samples and clinical data. In addition, more in vivo and in vitro experiments should been conducted in order to explore the functional role of the critical genes in HCC.

**Conclusions**

In this study, we assessed the metabolism-related genes expression profiles based on ICGC database and TCGA database. Moreover, a novel metabolism-related prognostic model was constructed, which could be as as an independent prognostic predictor for HCC. The prognostic value of metabolism-related prognostic model was further validated in TCGA database. Taken together, the findings herein may provide a novel prognostic model that would be effective in monitoring metabolism and predicting the prognosis in HCC patients.
Abbreviations

HCC: hepatocellular carcinoma; TCGA: The Cancer Genome Atlas (database); ICGC: the International Cancer Genome Consortium; MRGs: metabolism-related genes; OS: overall survival; ROC: Receiver operating characteristic; AUC: The area under the ROC curve; TNM: Tumour size/lymph nodes/distance metastasis, a tumour staging system used in oncology and constructed by the American Joint Committee on Cancer and the Union for International Cancer Control; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False discovery rate.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

All data used in this study were acquired from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) portal.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was supported by a Grant from the National Natural Science Foundation
of China (Grant 81700012; to Shenghui Qin)

Authors’ contributions

Shenghui Qin conceived of and directed the project, wrote the manuscript. Zhihao Wang performed data bioinformatics analyses. Kidane Siele Embaye et al helped with part of English writing and checking. All authors read and approved the manuscript.

Acknowledgements

Not applicable.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, 68:394-424.
2. Bruix J, Reig M, Sherman M: Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology 2016, 150:835-853.
3. Hanahan D, Weinberg RA: Hallmarks of Cancer: The Next Generation. Cell 2011, 144:646-674.
4. Jones RG, Thompson CB: Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes & Development 2009, 23:537-548.
5. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
6. Qu W, Oya S, Lieberman BP, Ploessl K, Wang L, Wise DR, Divgi CR, Chodosh LP, Thompson CB, Kung HF: Preparation and Characterization of L-5-C-11 -Glutamine for Metabolic Imaging of Tumors. Journal of Nuclear Medicine 2012, 53:98-105.
7. Kroemer G, Pouyssegur J: Tumor cell metabolism: Cancer’s Achilles’ heel. Cancer Cell 2008, 13:472-482.
8. Heiden MGV, Cantley LC, Thompson CB: Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 2009, 324:1029-1033.
9. Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G, Yin Z, Xie X, Wang X, Chen W, et al: A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology 2018, 67:662-675.
10. Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, Fan F, Jiao B, Xu G: Analysis of Urinary Metabolic Signatures of Early Hepatocellular Carcinoma Recurrence after Surgical Removal Using Gas Chromatography-Mass Spectrometry. Journal of Proteome Research 2012, 11:4361-4372.
11. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo
12. Noble WS: **How does multiple testing correction work?** *Nat Biotechnol* 2009, 27:1135-1137.

13. Harris MA, Clark JI, Ireland A, Lomax J, Ashburner M, Collins R, Eilbeck K, Lewis S, Mungall C, Richter J, et al: **The Gene Ontology (GO) project in 2006.** *Nucleic Acids Research* 2006, 34:D322-D326.

14. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K: **KEGG: new perspectives on genomes, pathways, diseases and drugs.** *Nucleic Acids Research* 2017, 45:D353-D361.

15. Yu G, Wang L-G, Han Y, He Q-Y: **clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters.** *Omics-a Journal of Integrative Biology* 2012, 16:284-287.

16. Sauerbrei W, Royston P, Binder H: **Selection of important variables and determination of functional form for continuous predictors in multivariable model building.** *Statistics in Medicine* 2007, 26:5512-5528.

17. Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM: **Time-varying covariates and coefficients in Cox regression models.** *Annals of Translational Medicine* 2018, 6.

18. Heagerty PJ, Lumley T, Pepe MS: **Time-dependent ROC curves for censored survival data and a diagnostic marker.** *Biometrics* 2000, 56:337-344.

19. Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Blal HA, Alm T, Asplund A, Bjork L, Breckels LM, et al: **A subcellular map of the human proteome.** *Science 2017, 356.*

20. Qin L, Qin S, Zhang Y, Zhang C, Ma H, Li N, Liu L, Wang X, Wu R: **p120 modulates LPS-induced NF-κB activation partially through RhoA in bronchial epithelial cells.** *Biomed Res Int* 2014, 2014:932340.

21. Qin S, Qin L, Zhang C, Liu L, Sun W, Li N, Wu R, Wang X: **p120-Catenin modulating nuclear factor-κB activation is partially RhoA/ROCK-dependent in scratch injury.** *Wound Repair Regen* 2015, 23:231-240.

22. Higgins BD, Kane MT: **Inositol transport in mouse embryonic stem cells.** *Reproduction Fertility and Development* 2005, 17:633-639.

23. Kasaian K, Wiseman SM, Walker BA, Schein JE, Zhao Y, Hirst M, Moore RA, Mungall AJ, Marra MA, Jones SJM: **The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.** *Bmc Cancer* 2015, 15.

24. Zhong Z, Cao Y, Yang S, Zhang S: **Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-κappa B signaling pathway.** *Pharmazie* 2016, 71:280-284.

25. Wang N, Zhan T, Ke T, Huang X, Ke D, Wang Q, Li H: **Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer.** *British Journal of Cancer* 2014, 110:1034-1044.

26. Tian H, Ge C, Li H, Zhao F, Hou H, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J: **Ribonucleotide Reductase M2B Inhibits Cell Migration and Spreading by Early Growth Response Protein 1-Mediated Phosphatase and Tensin Homolog/Akt1 Pathway in Hepatocellular Carcinoma.** *Hepatology* 2014, 59:1459-1470.

27. Liu X, Xu Z, Hou C, Wang M, Chen X, Lin Q, Song R, Lou M, Zhu L, Qiu Y, et al: **Inhibition
of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. Biochemical Pharmacology 2016, 103:118-128.

28. Yen CL, Farese RV, Jr.: MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine. J Biol Chem 2003, 278:18532-18537.

29. Cao JS, Lockwood J, Burn P, Shi YG: Cloning and functional characterization of a mouse intestinal Acyl-CoA : monoacylglycerol acyltransferase, MGAT2. Journal of Biological Chemistry 2003, 278:13860-13866.

30. Jaeger S, Wahl S, Kroeger J, Sharma S, Hoffmann P, Floegel A, Pischon T, Prehn C, Adamski J, Mueller-Nurasyid M, et al: Genetic variants including markers from the exome chip and metabolite traits of type 2 diabetes. Scientific Reports 2017, 7.

31. Yang M, Nickels JT: MOGAT2: A New Therapeutic Target for Metabolic Syndrome. Diseases (Basel, Switzerland) 2015, 3:176-192.

32. Lian W, Jin H, Cao J, Zhang X, Zhu T, Zhao S, Wu S, Zou K, Zhang X, Zhang M, et al: Identification of novel biomarkers affecting the metastasis of colorectal cancer through bioinformatics analysis and validation through qRT-PCR. Cancer Cell Int 2020, 20:105.

33. Ptáček LJ, George AL, Jr., Griggs RC, Tawil R, Kallen RG, Barchi RL, Robertson M, Leppert MF: Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell 1991, 67:1021-1027.

34. Vicart S, Sternberg D, Fontaine B, Meola G: Human skeletal muscle sodium channelopathies. Neurological Sciences 2005, 26:194-202.

35. Liang H, Chen HK, Shen YY, Feng QS, Jin W, Huang W, Zeng YX: A rare polymorphism of the COX7B2 gene in a Cantonese family with nasopharyngeal carcinoma. Science in China Series C-Life Sciences 2004, 47:449-453.

36. Al Safar HS, Cordell HJ, Jafer O, Anderson D, Jamieson SE, Fakiola M, Khazanehdari K, Tay GK, Blackwell JM: A Genome-Wide Search for Type 2 Diabetes Susceptibility Genes in an Extended Arab Family. Annals of Human Genetics 2013, 77:488-503.

37. Khan AA, Quigley JG: Heme and FLVCR-related transporter families SLC48 and SLC49. Molecular Aspects of Medicine 2013, 34:669-682.

38. Peng C, Song Y, Chen W, Wang X, Liu X, Wang F, Wu D, Ma S, Wang X, Gao C: FLVCR1 promotes the proliferation and tumorigenicity of synovial sarcoma through inhibiting apoptosis and autophagy. International Journal of Oncology 2018, 52:1559-1568.

39. Wei X, Ke J, Huang H, Zhou S, Guo A, Wang K, Zhan Y, Mai C, Ao W, Xie F, et al: Screening and Identification of Potential Biomarkers for Hepatocellular Carcinoma: An Analysis of TCGA Database and Clinical Validation. Cancer Manag Res 2020, 12:1991-2000.

Figure Legends

Fig.1 Differentially expressed metabolism-related genes (MRGs) in hepatocellular carcinoma (HCC).

Heatmap of MRGs between HCC and nontumor tissues in ICGC database(a) and TCGA
database (b). The color from blue to red represents the progression from low expression to high expression; Volcano plot of MRGs in ICGC database(c) and TCGA database(d). The red dots in the plot represents upregulated genes and blue dots represents downregulated genes with statistical significance. Black dots represent no differentially expressed genes. (e) Venn diagram showing the gene numbers of the MRGs of HCC in ICGC and TCGA database.

**Fig2. The GO and KEGG analysis of differentially expressed MRGs.**

(a) the top 10 of biological processes GO terms, cellular component GO terms, molecular function GO terms; (b) The correlation between intersection genes and top 5 biological processes GO terms; (c) The KEGG pathway analysis of differentially expressed MRGs;

**Fig3. Identification of survival-related differentially expressed MRGs by univariate Cox regression analysis.**

(a) Forest plot of hazard ratios showing survival-related MRGs. P values <0.001 are considered to be statistically significant; The expression of 17 metabolism-related prognostic genes between HCC and normal tissues in ICGC database(b) and TCGA database(c).

**Fig4 Establishment of metabolism-related prognostic signature.**

(a)Screening of optimal parameter (lambda) at which the vertical lines were drawn. (b)Lasso coefficient profiles of the seventeen MRGs with non-zero coefficients determined by the optimal lambda. (c)Multivariate analyses assessing relationship between expression levels of MRGs and overall survival (OS) in patients with HCC.
Fig. 5 Construction of the metabolism-based prognostic risk signature in the ICGC cohorts.

(a) The risk score distribution of HCC patients; (b) Survival status and duration of patients; (c) Heatmap of the metabolism-related genes expression; (d) Survival curves for the low risk and high risk groups; (e) Time-independent receiver operating characteristic (ROC) analysis of risk scores for prediction the overall survival in the ICGC set.

Fig. 6 Validation of the metabolism-based prognostic risk signature in the TCGA cohorts.

(a) The risk score distribution of HCC patients; (b) Survival status and duration of patients; (c) Heatmap of the metabolism-related genes expression; (d) Survival curves for the low risk and high risk groups; (e) Time-independent receiver operating characteristic (ROC) analysis of risk scores for prediction the overall survival in the TCGA set. (f) Univariate Cox regression analysis of discrete clinical factors; (g) Multivariate Cox regression analysis of discrete clinical factors.

Fig. 7 Verification of hub MRGs expression in HCC and normal liver tissue using the HPA database. (a): FLVCR1, (b): SLC5A11, (c): RRM2, (d): MOGAT2.

Fig. 8 Relationships between MRGs expression and clinicopathological factors in HCC (P < 0.05).

Fig. 9 Validation of hub genes by WB and qRT-PCR. WB(a) and qRT-PCR(b) validation of the expression of FLVCR1, SLC5A11 and RRM2 in cell lines.
